Warnings as deaths linked to party drug surge | SBS News
Deaths linked to GHB increased by tenfold between 2013 and 2022, according to a new study.
www.sbs.com.auI don’t have real-time access to the latest news right now, but I can summarize current directions in GHB overdose treatment and point you to recent sources you can check.
Short answer
- There is ongoing research into antidotes and targeted therapies for GHB overdose, focusing on blocking brain uptake of GHB via MCT inhibitors and exploring GABA-B receptor antagonist strategies. However, as of the latest comprehensive reviews, there is no widely approved specific antidote; management remains supportive and airway/respiratory support is critical.[1][2]
Key themes in recent research
- GABA-B receptor antagonism: Experimental studies have suggested that blocking GABA-B receptors could mitigate GHB-induced respiratory depression, but concerns remain about timing, toxicity, and clinical feasibility.[2]
- MCT1 transporter inhibition: Some preclinical work indicates that inhibiting monocarboxylate transporters (MCT1) may reduce GHB brain uptake and lessen toxicity, offering a potential antidote pathway, though this is not yet a clinically approved therapy.[1]
- Supportive care as standard: In many settings, treatment focuses on stabilization, airway management, spectroscopy of respiration, and careful monitoring until GHB is metabolized/cleared, given the lack of a universally approved antidote.[3][8]
Notable recent indicators by region
- Australia has seen rising GHB-related harms; studies highlight the increasing hospitalizations and deaths, underscoring the need for harm-reduction strategies and urgent clinical guidance in overdose cases.[7][9][10]
- Internationally, reviews and preclinical reports continue to examine pharmacological strategies, but clinical translation into standard care varies by country and regulatory approvals.[2][1]
Suggested next steps to stay updated
- Check recent peer-reviewed reviews on GHB overdose treatment in major medical journals (e.g., The Journal of Pharmacology and Experimental Therapeutics, Addiction, or Clinical Toxicology).
- Monitor health agency updates or NDARC/UNSW-type research outputs for country-specific trends and any emergent clinical guidelines.
- Look for clinical trial registrations or results on GHB antidotes or GABA-B antagonists to see if any move toward clinical use.
If you’d like, I can search for the very latest articles or synthesize a brief, up-to-date literature brief with citations from reputable sources. I can also tailor the overview to your location (Dallas/Texas) and local EMS/ED practices if that helps.